2026 International Spring Forum
April 15, 2026 | 12:00 PM EST
- Home
- Clinical Resources Search
- PQI: Epcoritamab (Epkinly®) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Epcoritamab (Epkinly®) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
About this PQI
The purpose of this PQI is to discuss the clinical considerations of epcoritamab (Epkinly®) to optimize the outcomes for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).

How to Use a Positive Quality Intervention (PQI)
Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.
Find a PQIFind Similar Resources
All Resources
PQI
PQI
PQI
PQI
PQI: Talectrectinib (Ibtrozi) for the Management of ROS1+ Advanced NSCLC
Author: Stefanie Houseknecht, PharmD, BCOP
Last Updated: 09/01/2025
PQI: Zanidatamab-hrii (Ziihera) for the Management of Biliary Tract Cancer
Author: Shelbie Gibbs, PharmD, BCOP
Last Updated: 09/01/2025
PQI: Prophylaxis and Management of Skin Toxicities with Amivantamab (Rybrevant) and Lazertinib (Lazcluze) Treatment: The COCOON Protocol
Author: Sharon Zhong, PharmD, BCOP
Last Updated: 09/01/2025
PQI: Encorafenib (Braftovi®) and Binimetinib (Mektovi®) for the Management of NSCLC
Author: Aubrey Lasko, PharmD, BCOP
Last Updated: 09/01/2025
PQI in Action
PQI in Action
PQI in Action
PQI in Action
PQI in Action: Fruquintinib (Fruzaqla®)
Author: Florida Cancer Specialists & Research Institute | Atlanticare Cancer Care Institute
Last Updated: 09/01/2025
PQI in Action: Management of Tucatinib (Tukysa®) and Trastuzumab in HER2-Positive Metastatic Colorectal Cancer – 2
Author: Johns Hopkins, MD | The University of Texas MD Anderson Cancer Center, TX
Last Updated: 09/01/2025
PQI in Action: Proactive Symptom Management in Myelofibrosis
Author: Cancer Specialists of North Florida
Last Updated: 09/01/2025
PQI in Action: Sonidegib (Odomzo®) Patient Management
Author: UCLA Medical Center | The Ohio State University Cancer Comprehensive Cancer Center (The James) | WVU Medicine
Last Updated: 09/01/2025
Treatment Support Kit
Treatment Support Kit
Treatment Support Kit
Treatment Support Kit
Treatment Support Kit: Elranatamab
Last Updated: 09/01/2025
Treatment Support Kit: Mirdametinib
Last Updated: 09/01/2025
Treatment Support Kit: Abemaciclib
Last Updated: 09/01/2025
Treatment Support Kit: Temozolomide
Last Updated: 09/01/2025
PQI
PQI
PQI
PQI
PQI: Advances in MRD Monitoring for Diffuse Large B-Cell Lymphoma (DLBCL)
Author: Tara Graff, DO, MS
Last Updated: 09/01/2025
PQI: Tafasitamab-cxix (Monjuvi®) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Author: Jeff Engle, PharmD, MS
Last Updated: 09/01/2025
PQI: Selinexor (Xpovio®) Patient Management
Author: Jeremiah Moore, PharmD
Last Updated: 09/01/2025
PQI: Loncastuximab tesirine-lpyl (Zynlonta®) in Relapsed/Refractory Large B-Cell Lymphoma
Author: Kelly Valla, PharmD, BCOP
Last Updated: 09/01/2025
PQI
PQI
PQI
PQI
PQI: Tazemetostat (Tazverik®) Management in Relapsed/Refractory Follicular Lymphoma
Author: Houston Holmes, MD
Last Updated: 09/01/2025
PQI: Obinutuzumab (Gazyva®) for Chronic Lymphocytic Leukemia and Follicular Lymphoma
Author: Renee Shirakawa Kwock, PharmD, BCOP
Last Updated: 09/01/2025
PQI: Initiating Mosunetuzumab-axgb (Lunsumio) in Relapsed/Refractory Follicular Lymphoma
Author: Sarah Rockwell, PharmD, BCOP
Last Updated: 09/01/2025
PQI: Duvelisib (Copiktra®) for Chronic Lymphocytic Leukemia
Author: Linda Frisk, PharmD
Last Updated: 09/01/2025
PQI
PQI Podcast
Treatment Support Kit
PQI
PQI: Talectrectinib (Ibtrozi) for the Management of ROS1+ Advanced NSCLC
Author: Stefanie Houseknecht, PharmD, BCOP
Last Updated: 09/01/2025
S9 E1: Head & Neck Cancer Care: Clinical Progress & Compassionate Practice
Author: Ginger Blackmon, PharmD | Deborah Wong, MD, PhD
Last Updated: 09/01/2025
Treatment Support Kit: Elranatamab
Last Updated: 09/01/2025
PQI: Zanidatamab-hrii (Ziihera) for the Management of Biliary Tract Cancer
Author: Shelbie Gibbs, PharmD, BCOP
Last Updated: 09/01/2025